CB 839

Drug Profile

CB 839

Alternative Names: CB839

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Calithera Biosciences
  • Developer Calithera Biosciences; Case Western Reserve University; M. D. Anderson Cancer Center; National Cancer Institute (USA)
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Leukaemia; Renal cell carcinoma
  • Phase I/II Colorectal cancer; Malignant melanoma; Myelodysplastic syndromes; Non-small cell lung cancer; Solid tumours
  • Phase I Haematological malignancies

Most Recent Events

  • 01 Jun 2018 Interim efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 18 May 2018 National Cancer Institute plans a phase I trial for Astrocytoma in February 2019 , (NCT03528642)
  • 21 Apr 2018 Pharmacodynamics data from a preclinical studies in Cancer presented at 109th American Association for Cancer Research Annual Meeting (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top